Blurbs

Analysts’ Top Healthcare Picks: Ocular Therapeutix (OCUL), Syros Pharmaceuticals (SYRS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCULResearch Report), Syros Pharmaceuticals (SYRSResearch Report) and Sutro Biopharma (STROResearch Report) with bullish sentiments.

Ocular Therapeutix (OCUL)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix, with a price target of $20.00. The company’s shares closed last Tuesday at $4.34, close to its 52-week low of $2.91.

According to TipRanks.com, Wolleben has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.1% and a 31.2% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $17.00.

See the top stocks recommended by analysts >>

Syros Pharmaceuticals (SYRS)

In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Syros Pharmaceuticals, with a price target of $19.00. The company’s shares closed last Tuesday at $0.87, close to its 52-week low of $0.65.

According to TipRanks.com, Cann is a 2-star analyst with an average return of -0.3% and a 42.4% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Caribou Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syros Pharmaceuticals with a $10.40 average price target, representing a 1004.6% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.

Sutro Biopharma (STRO)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma, with a price target of $20.00. The company’s shares closed last Tuesday at $5.52, close to its 52-week low of $3.33.

According to TipRanks.com, Benjamin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.2% and a 35.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $26.67, a 417.9% upside from current levels. In a report issued on June 28, Berenberg Bank also maintained a Buy rating on the stock with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCUL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos